Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Bortezomib Maintenance Therapy after Induction with R-CHOP, ARA-C and Autologous Stem Cell Transplantation in Newly Diagnosed MCL Patients, Results of a Multicenter Phase II HOVON Study

Jeanette K Doorduijn, MD PhD, Monique C. Minnema, MD PhD, Marie Jose Kersten, MD PhD, Pieternella J Lugtenburg, MD PhD, Martin R. Schipperus, MD PhD, Marinus van Marwijk Kooy, MD PhD, Marius MacKenzie, MD PhD, Josée M Zijlstra, MD, Henriette W Berenschot, MD, M. R Schaafsma, MD PhD, Dana A Chitu, PhD, Hanneke C. Kluin-Nelemans, MD PhD

Blood (2015) 126 (23): 339.

https://doi.org/10.1182/blood.V126.23.339.339

Published: 2015

Journal Articles

Validation Of a Multi-Diagnostic Approach Including Flow Cytometry To Identify Specific Risk Categories Within Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group

Eline M.P. Cremers, MD, Theresia M. Westers, PhD, Canan Alhan, MD, Claudia Cali, Heleen A. Visser-Wisselaar, PhD, Dana A Chitu, PhD, Marian J.P.L. Stevens-Kroef, PhD, Pedro Silva Coelho, MD, Edo Vellenga, MD, PhD, Saskia K. Klein, MD PhD, Pierre W. Wijermans, MD, PhD, Georgine E. de Greef, MD, PhD, Martijn R. Schaafsma, MD, PhD, M Marwijk Kooy, MD, PhD, Petra Muus, MD, PhD, Gert J. Ossenkoppele, MD PhD, Joop H. Jansen, PhD, Arjan A. van de Loosdrecht, MD, PhD

Blood (2013) 122 (21): 1521.

https://doi.org/10.1182/blood.V122.21.1521.1521

Published: 2013

Journal Articles

Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial

Henk Lokhorst, Bronno van der Holt, PhD, Sonja Zweegman, MD PhD, Edo Vellenga, MD, PhD, Sandra Croockewit, MD, Marinus H.J. Van Oers, MD, PhD, Peter von dem Borne, MD, PhD, Pierre W. Wijermans, MD, PhD, M. R Schaafsma, MD, PhD, Okke de Weerdt, Shulamiet Wittebol, MD, Michel Delforge, MD, PhD, Gerard M.J. Bos, Prof MD PhD, Harm Sinnige, Marinus MarwijkKooy, Peter Joosten, MD, Monique C. Minnema, MD PhD, Rianne Ammerlaan, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 3332.

https://doi.org/10.1182/blood.V122.21.3332.3332

Published: 2013

Journal Articles

Identification Of Chromosomal Abnormalities By Microarray-Based Genomic Profiling As Compared To Karyotyping In Patients With Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group

Marian J.P.L. Stevens-Kroef, PhD, Annet Simons, Najat El Idrissi-Zaynoun, Bert A. van der Reijden, Eline M.P. Cremers, MD, Canan Alhan, Theresia M. Westers, Heleen A. Visser-Wisselaar, PhD, Dana Chitu, Edo Vellenga, S. K. Klein, Pierre W. Wijermans, MD, Georgine E. De Greef, Martyn R. Schaafsma, M. van Marwijk Kooy, Petra Muus, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Joop H. Jansen, PhD

Blood (2013) 122 (21): 1338.

https://doi.org/10.1182/blood.V122.21.1338.1338

Published: 2013

Journal Articles

Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program,

Blood (2011) 118 (21): 3841.

https://doi.org/10.1182/blood.V118.21.3841.3841

Published: 2011

Journal Articles

Effect of Thalidomide with Melphalan and Prednisone on Health-Related Quality of Life (HRQoL) in Elderly Patients with Newly Diagnosed Multiple Myeloma: A Prospective Analysis In a Randomized Trial

S. Verelst, F. Termorshuizen, C. Uyl-de Groot, M. R Schaafsma, R. Ammerlaan, S. Wittebol, H. Sinnige, S. Zweegman, M. van Marwijk Kooy, R. van der Griend, H. Lokhorst, P. Sonneveld, P. Wijermans

Blood (2010) 116 (21): 2972.

https://doi.org/10.1182/blood.V116.21.2972.2972

Published: 2010

Journal Articles

Achievement of Complete Response Is a Strong Prognostic Factor In Elderly Newly Diagnosed Myeloma: Retrospective Analysis of 1175 Patients

Blood (2010) 116 (21): 1949.

https://doi.org/10.1182/blood.V116.21.1949.1949

Published: 2010

Journal Articles

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison

Blood (2009) 113 (6): 1375–1382.

https://doi.org/10.1182/blood-2008-07-168625

Published: 2009

Includes: Supplemental data

Journal Articles

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

Blood (2008) 112 (11): 653.

https://doi.org/10.1182/blood.V112.11.653.653

Published: 2008

Journal Articles

ATP Dependent Interferon Responsive (ADIR) Gene Encodes an Activation Induced Minor Histocompatibility Antigen Recognized on Multiple Myeloma by CD8+ T Cells.

Cornelis A. Van Bergen, Michel G. Kester, Inge Jedema, Mirjam H. Heemskerk, Simone A. Van Luxemburg, Freke M. Kloosterboer, Erik W. Marijt, Arnoud H. De Ru, Martyn R. Schaafsma, Roelof Willemze, Peter A. Van Veelen, J.H. Frederik Falkenburg

Blood (2006) 108 (11): 549.

https://doi.org/10.1182/blood.V108.11.549.549

Published: 2006

Journal Articles

Primary Allogeneic T-Cell Responses Against In Vitro Modified Mantle Cell Lymphoma (MCL) Cells: Implications for Adoptive Immunotherapy after HLA-Matched Stem Cell Transplantation (SCT).

M. Hoogendoorn, MD, J. Olde Wolbers, W. M. Smit, MD PhD, I. Jedema, PhD, M. R. Schaafsma, MD PhD, R. M.Y. Barge, MD PhD, R. Willemze, MD PhD, J. H.F. Falkenburg, MD PhD

Blood (2004) 104 (11): 2118.

https://doi.org/10.1182/blood.V104.11.2118.2118

Published: 2004

Journal Articles

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study

Blood (2003) 101 (6): 2144–2151.

https://doi.org/10.1182/blood-2002-03-0889

Published: 2003

NARROW

Bortezomib Maintenance Therapy after Induction with R-CHOP, ARA-C and Autologous Stem Cell Transplantation in Newly Diagnosed MCL Patients, Results of a Multicenter Phase II HOVON Study

Validation Of a Multi-Diagnostic Approach Including Flow Cytometry To Identify Specific Risk Categories Within Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group

Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial

Identification Of Chromosomal Abnormalities By Microarray-Based Genomic Profiling As Compared To Karyotyping In Patients With Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group

Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program,

Effect of Thalidomide with Melphalan and Prednisone on Health-Related Quality of Life (HRQoL) in Elderly Patients with Newly Diagnosed Multiple Myeloma: A Prospective Analysis In a Randomized Trial

Achievement of Complete Response Is a Strong Prognostic Factor In Elderly Newly Diagnosed Myeloma: Retrospective Analysis of 1175 Patients

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

ATP Dependent Interferon Responsive (ADIR) Gene Encodes an Activation Induced Minor Histocompatibility Antigen Recognized on Multiple Myeloma by CD8+ T Cells.

Primary Allogeneic T-Cell Responses Against In Vitro Modified Mantle Cell Lymphoma (MCL) Cells: Implications for Adoptive Immunotherapy after HLA-Matched Stem Cell Transplantation (SCT).

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only